Affiliation:
1. Université de Reims Champagne-Ardenne, UFR de Pharmacie, BioSpecT EA 7506, 51097 Reims, France
2. CHU Reims, Department of Pharmacy, 51097 Reims, France
Abstract
Melanoma is the most common cause of death in skin cancer due to its high metastatic potential. While targeted therapies have improved the care of patients with metastatic melanoma harboring the BRAFV600E mutation, these treatments are associated with a high frequency of resistance. Resistance factors are related to cellular adaptation as well as to changes in the tumor microenvironment. At the cellular level, resistance involves mutations, overexpression, activation, or inhibition of effectors involved in cell signaling pathways such as MAPK, PI3K/AKT, MITF, and epigenetic factors (miRNAs). In addition, several components of the melanoma microenvironment, such as soluble factors, collagen, and stromal cells also play a crucial role in this resistance. In fact, extracellular matrix remodeling impacts the physical and chemical properties with changes in the stiffness and acidity, respectively of the microenvironment. The cellular and immune components of the stroma are also affected, including immune cells and CAF. The aim of this manuscript is to review the mechanisms responsible for resistance to targeted therapies in BRAFV600E-mutated metastatic melanoma.
Reference68 articles.
1. Mutations of the BRAF gene in human cancer;Davies;Nature,2002
2. The Cancer Genome Atlas Network (2015). Genomic Classification of Cutaneous Melanoma. Cell, 161, 1681–1696.
3. Melanoma: From mutations to medicine;Tsao;Genes Dev.,2012
4. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma;Long;J. Clin. Oncol.,2011
5. The role of BRAF V600 mutation in melanoma;Ascierto;J. Transl. Med.,2012
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献